Used in the development of targeted protein degradation therapies, particularly in the design of proteolysis-targeting chimeras (PROTACs). Its structure enables conjugation between a target-binding ligand and an E3 ubiquitin ligase recruiter, facilitating the degradation of disease-related proteins. The PEG3 linker enhances solubility and provides flexibility, improving cellular permeability and binding efficiency. The primary amine group allows for easy attachment to various functional moieties, making it valuable in creating novel therapeutics for cancer and other diseases involving protein dysregulation.